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Background: Recurrent T1-2 Nasopharyngeal Carcinoma (rT1-2) may be salvaged by 3D – CRT (3D-Conformal
Radiotherapy), IMRT (Intensity Modulated Radiotherapy), Brachytherapy (BT), BT with external radiotherapy. The
purpose of this study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC.
Methods: 168 patients, median age 48 years (range 16–75 years) proven rT1-2 NPC were diagnosed and treated
with four different irradiation modalities (3D-CRT, IMRT, BT, BT with external radiotherapy). Median time to recurrence
was 30 months (range 1–180 months). The median follow-up time was 28 months (range, 4–135 months).
Results: 161 patients completed a median dose of 6445 cGy (ranging 30 to 87 Gy). Seven patients prematurely
terminated their treatment due to acute side-effects and received 30–49 Gy. The 1- and 3-year local regional recurrent
free survival (LRRFS), distant free survival (DFS), and overall survival (OS) rates were 82.03% vs. 82.03% vs. 82.58%, 51.33%
vs. 51.33% vs. 53.41, respectively. Gender and recurrence T-classification were the two significant adverse prognostic
factors for LRRFS, DFS, and OS rates. Grade 3 or 4 toxicities were tolerable.
Conclusion: 3D-CRT, IMRT, BT, BT with external radiotherapy are feasible and efficacious for rT1-2 NPC. In toxicity
3D-CRT/IMRT group is lower than BT group. IMRT is superior for rT1-2 NPC.
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Nasopharyngeal carcinoma (NPC) is considered an en-
demic carcinoma in Southern China. Fujian province is one
of the high incidence regions for NPC [1]. It is a radiosensi-
tive disease and radiation therapy is the mainstay treatment
of non-metastatic NPC. The 5-year OS rate ranges from
75-82% for NPC patients. The local recurrence-free survival
rate exceeds 90% [2]. Despite the high efficacy in locoregio-
nal disease control with high-dose radiation, local recur-
rence remains a major cause of treatment failure for T1-2.* Correspondence: panjianji@aliyun.com
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unless otherwise stated.However, treatment of NPC recurrence, even in early
T stage, poses a challenge [3].
Various strategies, including surgery [4] (i.e., nasophar-
yngectomy), brachytherapy (BT) [5], stereotactic radio-
surgery [6] and external radiation [7,8], have been used
in an attempt to cure local early recurrent NPC. Consid-
ering the nasopharynx structure, small tumors may be
difficult to access. In addition, high dose re-irradiation
will have extensive side effects. Therefore, only a few pa-
tients accept nasopharyngectomy or stereotactic radio-
surgery. Re-irradiation remains an important modality
for re-treatment. 3D-Conformal Radiotherapy (3D-CRT)
[6]. Intensity Modulated Radiotherapy (IMRT) [6,9] and
brachytherapy (BT), are often utilized for nasopharynx
local small lesions, and treatment enables the delivery of
high-dose radiation to the target volume(s) while pro-
tecting normal radio-sensitive normal tissue and organs.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of cohort
Number %
Age, year
























Brachy + ER 53 31.5%
Dose (Gy)
<60 39 23.2%
≥ 60 129 76.8%
Abbreviation: ER external radiation, 3D-CRT three-dimensional conformal
radiotherapy, IMRT intensity modulated radiotherapy, Brachy Brachytherapy.
Table 2 The patient distribution number of 3D-CRT, IMRT
and BT +/− ER group
T 3D-CRT IMRT BT +/− ER X2 P value
1 + 2 32 17 47 4.117 0.128
3 + 4 35 11 26
Abbreviation: BT +/− ER brachytherapy +/− external radiotherapy.
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control and treatment-induced side effects from re-
irradiation modalities in rT1-2 NPC is scant [10].
The aim of this study is (1) to document the outcome
for 4 re-irradiation treatment modalities for rT1-2 NPC
treated with 3D-CRT, IMRT, BT, and BT with external
radiation, (2) to assess efficacy and late toxicities and (3)
to determine which one is the best treatment method.
We have large sample of 168 cases of rT1-2 NPC, all
from Fujian Provincial Cancer Hospital, with strong
homogeneity between 1996 and 2009.
Methods
Patients and pretreatment evaluation
Between January 1996 and June 2009, a total of 168 pa-
tients (median age 48 years, range 16–75 years) with histo-
logical proven local (rT1-2) NPC were diagnosed and
treated with four different irradiation modalities (3D-CRT,
IMRT, BT, and BT with external radiotherapy). Pretreat-
ment evaluation includes electrocardiogram, urinalysis,
disease history, bone scan, routine examination, blood
counts, serum electrolytes, chest X-ray, fiberoptic naso-
pharyngoscopy, head and neck CT scan, and ultrasound
or CT of the abdomen. In addition, magnetic resonance
imaging (MRI) scans of the head and neck were applied
instead of CT in all patients after July 2005. Other exami-
nations and studies such as position emission tomography
(PET) scans were performed at the treating physician’s dis-
cretion. NPC recurrence was histologically confirmed in
all cases through biopsy of the recurrent foci at the poster-
ior nasal space. Biopsy of the neck adenopathy was not
performed for the ten patients who presented with re-
gional recurrence. All cases were restaged according to
the American Joint Cancer Committee (AJCC) 1997 sta-
ging classification. The characteristics of the 168 patients
are detailed in Tables 1 and 2.
Ethics
The research had been performed with the approval of
Fujian Cancer Hospital Ethics Committee of Fujian Medical
University. The reference number is FJCH-09911. Written
informed consent was obtained from each patient. If the
patients were children, written informed consent was ob-
tained from their guardians.
Irradiation therapy
All patients (3D-CRT, IMRT) were fixed in the supine
position with thermoplastic masks. CT simulations with
intravenous contrast using 3 mm cuts from the vertex
to 2 cm below the clavicular heads were performed.
MRI-CT fusions using the Oncentra Masterplan co-
registration software (Oncentra Masterplan® version 1.5,
Nucletron BV) were conducted for all cases treated after
July 2005.The gross tumor volume on the primary site and neck
(GTV-P and GTV-N, respectively) included all disease
visualized either on CT or MRI or both CT and MRI.
Clinical target volumes (CTVs) of both GTV-P and
GTV-N included microscopic disease by adding up to
8–10 mm to GTVs. However, smaller margins around
3 mm were allowed when CTVs are near critical organs,
such as the brain stem or the spinal cord. High-risk
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possible. An additional 3 mm margin was extended to
CTVs to create the planning target volume (PTV) to
allow for a setup variability and internal motion.
Endanger normal structures including the optic nerves
and chiasm, brainstem, spinal cord, temporal lobes, eye-
balls and lens, pituitary gland, temporomandibular joints
(TMJ), as well as parotid glands were delineated and
described as organs at risk (OARs) during planning.
Total dose to the spinal cord, brainstem, and temporal
lobes, optic nerve/chiasm, TMJ, eyeballs and lens were
required to be measured during planning and their
limitation was individualized based on doses delivered
from the primary radiation therapy. Inverse treatment
planning using the Plato® treatment planning software
system (RTS® version 2.6.4) and a mono-isocentric tech-
nique was used for every patient in this cohort. The iso-
center was set at the center of the GTV-P. Minimal
planned doses between 50 and 60 Gy (2 Gy or 1.8 Gy
per daily fraction, five days per week) were prescribed to
the PTV(s) for all patients. The PTV(s) were treated
with step-and-shoot IMRT using 5–7 coplanar beams,
using a computer-controlled auto sequence multi-leaf
collimator (MLC) on a linear accelerator (Elekta Precise®,
Elekta AB) contained with a 40-leaf MLC. A treatment
plan of a patient with local recurrence only is illustrated
in Figures 1 and 2.
The hyperfraction radiation refers to treatment twice
or more than twice every day, with an interval of at least
six hours, each fraction lower than the routine dose,
compared with the conventional dose. It has similar or
higher total tumor radiation dose and aims to decrease
toxicities and increase the tumor control rate. Our cen-
ter was the first in China to adopt twice daily fractions,
with intervals of six hours between the two fractions
with the aim of reducing late damage.
Follow-up
All patients were followed up on a weekly basis during
their treatments. Then, they met their attending physi-
cians three months in the first two years and 6 months
for additional three to five years, and annually after five
years according to our therapeutic protocols. A complete
examination, as previous described, was requested at
each follow-up as well. Meanwhile, side effects to treat-
ment were evaluated according to the RTOG/EORTC
radiation morbidity scoring criteria at each follow-up
according to Cox [11].
Statistics
The local regional recurrence-free survival (LRRFS),
disease-free survival (DFS), and overall survival (OS)
rates were estimated with the Kaplan-Meier method.
Log-rank tests were performed to detect differences insurvival among different prognosticators. Multivariate ana-
lysis using the Cox proportional hazard model was per-
formed for all prognostic factors. Level of significance was
set at a 2-tailed P value of <0.05. All analyses were con-
ducted using the Statistical Package for the Social Science
(SPSS) software, version 17.0 (SPSS, Chicago, USA).
Results
Treatment outcome
The median follow-up time for the entire group was
28 months (range, 4–135 months). One hundred and
sixty-one patients completed their planned radiation to a
median dose of 6445 cGy. Seven patients prematurely
terminated their treatment due to acute side-effects and
received doses between 30-49 Gy. The 1-, 3-, and 5-year
LRRFS were 82.03% vs. 82.03% vs. 82.58%, DFS 51.33%
vs. 51.33% vs. 53.41, and OS 35.52% vs. 34.85% vs.
37.99%, respectively. At the time of this analysis, 92
(54.8%) were deceased; 37 due to progressive/recurrent
local diseases, 26 due to distant metastasis, 5 due to sec-
ondary primary malignancies, 3 due to an accident, 10
because of excessive nasal bleeding, and 8 due to other
medical conditions. Unfortunately, there were three
death cases with no detail medical records. Of the
remaining 76 surviving patients at the time of censor-
ship, 6 had local recurrence after re-irradiation and one
developed distant bone metastasis.
Prognostic factors
These prognostic factors, including age, gender, and
T-Classification at the initial diagnosis and recurrence,
time to recurrence, the dose, and the modalities of re-
irradiation on predicting local control (LC), DFS, and OS
were evaluated by both univariate and multivariate ana-
lyses. Gender and recurrence T-classification were the two
significant adverse prognostic factors for LC, DFS, and OS
rates in both univariate and multivariate analyses, whereas
the modalities of re-irradiation including four salvage
radiotherapy techniques were not statistically different for
LC, DFS, and OS rates (Tables 3 and 4).
Toxicities
All patients except 7 tolerated their re-irradiation well
and completed the planned therapy. The seven patients
terminated their treatment between 30 Gy and 49 Gy due
to acute mucositis. Severe adverse effects (defined as
Grade 3 or 4 toxicities described by the RTOG/EORTC
late toxicity criteria) were observed after 3 months fol-
lowing the completion of re-irradiation and included: 23
patients (13.7%) with ulceration in the posterior nasal
space, 29 patients (17.3%) with cranial nerve palsy, 22
patients (13.1%) with trismus, and 27patients (16.1%)
with hearing deficit [11]. As all patients presented with
xerostomia after their primary radiation therapy, severity
Figure 1 CT simulation images of a patient with rT2N0M0 NPC. A: Transverse CT simulation images at the levels of superior levels of the
nasopharynx illustrating target volumes, normal structures and isodose lines showing doses per fraction. B and C: Coronal (B) and Sagittal (C) CT
simulation images illustrating target volumes, normal structures and isodose lines showing doses per fraction.
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lyzed (Table 5). We divided the cohort toxicity into three
groups; 3D-CRT, IMRT and brachytherapy and/or exter-
nal radiation (BT +/− ER). We found the nasopharyngealulcer, cranial nerve palsy and hearing deficit is a signifi-
cant difference among the three groups; the 3D-CRT and
IMRT group had a lower incidence than the BT +/−
ER group. The trismus was similar in the three groups.
Figure 2 Dose-volume histogram of the same patient.
Table 3 Univariate analysis of potential prognostic factors
OS DFS LC
Item n Mean survival time ± SE P value Mean survival time ± SE P value Mean survival time ± SE P value
Gender 0.013 0.018 0.015
Male 136 65 ± 5 61 ± 5 62 ± 5
Female 32 40 ± 7 38 ± 6 38 ± 6
Age (y) 0.858 0.868 0.779
<50 93 58 ± 6 55 ± 5 55 ± 5
≥50 75 60 ± 7 57 ± 6 58 ± 7
T- classification 0.795 0.647 0.720
1 + 2 96 68 ± 9 54 ± 5 55 ± 5
3 + 4 72 56 ± 5 62 ± 7 62 ± 7
rT- classification 0.057 0.232 0.186
1 65 65 ± 7 58 ± 6 60 ± 6
2 103 54 ± 5 53 ± 5 53 ± 5
Time to recurrence 0.38 0.293 0.334
<36 months 65 66 ± 7 64 ± 7 64 ± 7
≥36 months 103 55 ± 5 51 ± 5 52 ± 5
Treatment 0.707 0.749 0.715
3D-CRT 67 56 ± 7 56 ± 7 56 ± 7
IMRT 28 55 ± 7 55 ± 7 55 ± 7
Brachy 20 59 ± 9 47 ± 8 47 ± 8
Brachy + ER 53 60 ± 7 57 ± 7 58 ± 7
Dose (Gy) 0.304 0.221 0.246
<60 48 68 ± 9 66 ± 9 66 ± 9
≥60 120 56 ± 5 52 ± 5 53 ± 5
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Table 4 Multivariate analysis of potential prognostic factors
Endpoint Factors B SE WALD Df Sig Exp(B) 95%CI EXP(B) Lower upper
OS Gender −0.74 0.258 8.312 1 0.004 0.475 0.286 0.788
rT- classification 0.682 0.274 6.208 1 0.013 1.978 1.157 3.382
DFS Gender −0.67 0.25 7.135 1 0.008 0.511 0.312 0.836
rT- classification 0.58 0.26 4.948 1 0.026 1.786 1.071 2.977
LRRFS Gender −0.70 0.25 7.764 1 0.005 0.496 0.303 0.812
Rt- classification 0.619 0.26 5.536 1 0.019 1.857 1.109 3.11
Abbreviations: OS overall survival, DFS disease-free survival, LRRFS locoregional recurrence free survival.
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the toxicity, but the difference was not statistically signifi-
cant [11].
Discussion
Fujian province of Southern China is a high incidence re-
gion for NPC. The 168 cases of recurrent T1-2 NPC were
all from Fujian Provincial Tumor Hospital between 1996
and 2009 and had strong homogeneity. In this series of
168 patients diagnosed with locally recurrent T1-2 NPC
and previously treated with a definitive dose of radiation,
high-dose re-irradiation with 3D-CRT, IMRT, BT, and
BT with external radiotherapy is feasible and efficacious.
The estimated LRRFS, DFS and OS rates at 1-, 3-, and
5 years were 82.03%, 82.03%, and 82.58%, 51.33%, 51.33%,
and 53.41%, 35.52%, 34.85%, and 37.99%, respectively.
Multivariate analyses revealed that gender and recurrent
T-classification were two significant prognosticators for
both LC and OS after re-irradiation. Additionally, most
patients tolerated their retreatment, although a significant
minority still suffered at least one moderate to severe late
radiation toxicity.
Local recurrence of NPC in the post-nasal space and
base of skull poses a major challenge for treatment;
nevertheless, retrospective evidence from a large series
suggests that salvage treatment for isolated local recur-
rences may improve survival, especially for small (rT1-2)
volume recurrent disease [3]. For tumors localized to the
nasopharynx, surgery or brachytherapy may be viable
options. Good tumor control with acceptable morbidities
has been reported with salvage nasopharyngectomiesTable 5 T comparison of late radiation complications on
three groups







Nasopharyngeal necrosis 4 (6.0%) 1 (3.6%) 18 (24.7%) 0.001
Cranial nerve palsy 7 (10.4%) 2 (7.1%) 20 (27.4%) 0.008
Trismus 9 (13.4%) 4 (14.3%) 9 (12.3%) 0.961
Hearing deficit 6 (9.0%) 2 (7.1%) 19 (26.0%) 0.008performed in expert centers, intra-cavitary or interstitial
brachytherapy are alternative modalities for limited local
recurrences [12]. Law et al. recently published their
series of intra-cavitary mold brachytherapy with 50-
55 Gy using a 192Ir source, and demonstrated a 5-year
local control rate of 85% and a major complication rate
of 47% [13]. In addition, Leung et al. described salvage
therapy with a combination of high-dose-rate (HDR)
intra-cavitary brachytherapy and external beam radiation
therapy, and found that a higher radiation dose and a
smaller recurrence was associated with improved out-
comes [14]. Stereotactic radiosurgery or radiotherapy
have also been employed to treat locally recurrent NPC
[15]. This highly precise technique allows a delivery of
ablative radiation doses with a rapid fall-off and is well
suited to the clinical situation where critical structures
lie in proximity to the posterior nasal space. Addition-
ally, where the tumor can be well visualized with fusion
MRI/CT imaging and sufficient immobilization can be
achieved is excellent for using customizable framed or
frameless solutions. Multiple series have shown good ef-
ficacy, with 2-year local control rates ranging from 55%
to 92%. However, morbidity after radiosurgery can be
considerable, which may include carotid or cerebral
hemorrhage, cranial neuropathy, massive epistaxis, naso-
pharyngeal necrosis, temporal lobe necrosis, and osteor-
adionecrosis of the skull base. Some of these severe
toxicities may be related to the large fraction size used
in previously heavily irradiated normal tissues [16].
All of the above-mentioned techniques may be applied
for selected cases, especially for smaller volume recur-
rences within the nasopharynx within specialist centers.
3D-CRT and IMRT are advanced techniques that enable
the delivery of satisfactory high-dose radiation to the tar-
get volume(s) while defending normal OARs. Conse-
quently, they potentially improve the radiotherapy effect
[17]. The clinical superiority of IMRT as a primary treat-
ment technique with respect to both disease control and
side effects has been repeatedly proved for newly diag-
nosed NPC [18-20]. The literature indicates IMRT is
superior to 3D-CRT in planning the target and late tox-
icity [17,21]. Re-irradiation of NPC local recurrence
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documented in 3 preliminary reports. The initial experi-
ence of 49 patients with recurrent NPC reported by Lu
et al. [22] indicated that a sufficient coverage of tumor
volume could be achieved using IMRT. Locoregional
control rate of 100% was observed at the average dose of
71.4 Gy to GTV and a median follow-up time of nine
months, Another previous article mentioned 31 patients
with locally recurrent NPC treated with IMRT to a me-
dian dose of 54 Gy resulted in one-year locoregional
progression-free and OS rates of 56% and 63%, respect-
ively, after a median follow-up of 11 month [23]. In our
previous paper, 70 patients were proven locally recurrent
NPC with radiologic or pathologically when cured with
IMRT [24]. The median time to recurrence was 30 months.
Fifty-seven percent of the patients were classified as rT3-
4. The minimum planned doses were 59.4 to 60 Gy in
1.8 Gy to 2 Gy fractions to the gross disease, with or with-
out chemotherapy. The median dose to the tumor was
70 Gy (range, 50–77.4 Gy). With a median follow-up time
of 25 months, the 2-year LRRFS, DFS, and OS rates were
65.8%, 65.8%, and 67.4%, respectively. Moderate to severe
late side effects were noted in 25 patients (35.7%). Ex-
tended disease-free interval and advanced T classification
at presentation were adverse prognostic factors. Han et al.
investigated 239 local recurrence NPC patients with IMRT
and claimed 5-year local recurrence-free survival (LRFS),
distant metastasis-free survival (DMFS), DFS and OS rates
were 85.8%, 80.6%, 45.4%, and 44.9% respectively [9]. All
researchers have concluded that retreatment using IMRT
is feasible and tolerated for patients who have experienced
a definitive dose of radiation using a conventional tech-
nique for their primary treatment of NPC. In our study,
there is no statistically significant difference among the
four retreatment modalities for LC, DFS, and OS rates, be-
cause the four methods are all accurate radiotherapy, T1-2
patients recurrent target area tumors are small and easy to
treat [17]. We may not detect a better effect of IMRT be-
cause the number of patients receiving IMRT is only 28,
and we need more IMRT patients to confirm the results.
Our results indicated gender and recurrent T classifica-
tion alone are not good prognostic factors. Males have a
better prognosis than female because males have better
tolerance of radiation than females. Our study shows that
the extent of recurrent disease (i.e., rT-classification) was
significant for predicting treatment outcome. The rT-
classification of our patients was defined using the AJCC
system for NPC, which is largely designed for initial sta-
ging. There are many published studies that indicate the
earlier T classification of recurrent tumors, the better the
prognosis [25-27]. We find that the toxicity that manifests
as nasopharyngeal ulcer and cranial nerve palsy is signifi-
cantly different between the BT group and non-BT group
(3D-CRT, IMRT group). The toxicity in the non-BT groupis lower than in the BT group. The trismus is similar in
both groups. So we prefer to use 3D-CRT or IMRT rather
than brachytherapy in rT1-2 NPC [25]. Chen et al. shows
late toxicities are higher in a three-dimensional conformal
group than in an intensity-modulated radiotherapies
group for nasopharyngeal carcinoma [10]. In our study
IMRT group had a lower incidence than 3D-CRT group in
the toxicity, but the difference was not statistically signifi-
cant. Because the number of patients receiving IMRT is
only 28, we need more IMRT patients to confirm the re-
sults. Considering the balance of efficacy and toxicities, we
think IMRT is the best choice for rT1-2 nasopharyngeal
carcinoma.
Despite the relatively large sample size of this group of
patients with locally recurrent T1-2 NPC, a number of
pitfalls need to be discussed. The follow-up time of
28 months is relatively short for long-term outcome in
head and neck cancer management. Nevertheless, in
most cases, local recurrences of nasopharyngeal cancer
occur in the first two years after IMRT treatment [26].
In fact, our observation period with a median follow-up
time of 28 months may be adequate. Furthermore, this
retrospective series may be with analysis inherent biases
in nature.
Our results are far from conclusive and a number of
critical questions need to be answered. Tian et al. [26]
described a retrospective series of 251 patients with IMRT
of locally recurrent NPC. The mean dose to the GTV was
70.04 Gy (61.73-77.54 Gy), but the re-irradiation dose is
not prognostic factors. Chen et al. [28] demonstrated that
IMRT with 70 Gy was efficient for local tumor control.
However, they observed a high frequency of serious late
complications. In our results, the prognosis of the high
dose group is not better than that of a low-dose group. So
how much is the best reasonable dose, and whether
patients with recurrence needed high dose radiation is
controversial. Clearly the optimal dose for disease control
in re-irradiation for locally recurrent NPC needs to be
determined.
Conclusion
Four modes of re-irradiation treatment (3D -CRT, IMRT,
BT, and BT with external radiotherapy) are feasible and
efficacious for recurrent T1-2 Nasopharyngeal carcin-
oma. For toxicity, the 3D-CRT/IMRT group is lower
than the BT group. IMRT is superior for recurrent T1-2
nasopharyngeal carcinoma.
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